David Stanton
Stock Analyst at Jefferies
(4.38)
# 1,314
Out of 4,683 analysts
234
Total ratings
52.4%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by David Stanton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: TLX Telix Pharmaceuticals Limited | Maintained: Buy | $29.00 → $29.30 | $15.58 | +88.06% | 24 | Aug 21, 2026 | |
| ASX: COH Cochlear Limited | Maintained: Hold | $128.40 → $144.75 | $137.76 | +5.07% | 20 | Aug 20, 2026 | |
| ASX: CSL CSL Limited | Maintained: Hold | $119.00 → $146.50 | $173.88 | -15.75% | 25 | Aug 20, 2026 | |
| ASX: HLS Healius Limited | Maintained: Hold | $0.38 → $0.41 | $0.44 | -5.75% | 18 | Aug 20, 2026 | |
| ASX: PME Pro Medicus Limited | Maintained: Hold | $188.25 → $196.95 | $179.24 | +9.88% | 6 | Aug 20, 2026 | |
| ASX: SHL Sonic Healthcare Limited | Maintained: Hold | $23.00 → $21.00 | $20.10 | +4.48% | 22 | Aug 20, 2026 | |
| ASX: IDX Integral Diagnostics Limited | Maintained: Buy | $3.70 → $3.50 | $2.33 | +50.21% | 10 | Aug 11, 2026 | |
| ASX: NEU Neuren Pharmaceuticals Limited | Maintained: Buy | $28.80 → $29.40 | $21.02 | +39.87% | 18 | Aug 5, 2026 | |
| ASX: CUV Clinuvel Pharmaceuticals Limited | Maintained: Buy | $39.20 → $40.80 | $9.18 | +344.44% | 11 | Jul 28, 2026 | |
| ASX: MSB Mesoblast Limited | Maintained: Buy | $2.80 → $3.00 | $2.41 | +24.48% | 16 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $34.50 → $39.80 | $50.06 | -20.50% | 12 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5.00 → $5.60 | $2.34 | +139.32% | 12 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $0.80 → $0.83 | $0.67 | +23.88% | 11 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.05 → $3.30 | $2.62 | +25.95% | 17 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2.10 → $0.04 | $0.05 | -20.00% | 8 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $16.84 | n/a | 1 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.35 | n/a | 3 | Apr 8, 2021 |
Telix Pharmaceuticals Limited
Aug 21, 2026
Maintained: Buy
Price Target: $29.00 → $29.30
Current: $15.58
Upside: +88.06%
Cochlear Limited
Aug 20, 2026
Maintained: Hold
Price Target: $128.40 → $144.75
Current: $137.76
Upside: +5.07%
CSL Limited
Aug 20, 2026
Maintained: Hold
Price Target: $119.00 → $146.50
Current: $173.88
Upside: -15.75%
Healius Limited
Aug 20, 2026
Maintained: Hold
Price Target: $0.38 → $0.41
Current: $0.44
Upside: -5.75%
Pro Medicus Limited
Aug 20, 2026
Maintained: Hold
Price Target: $188.25 → $196.95
Current: $179.24
Upside: +9.88%
Sonic Healthcare Limited
Aug 20, 2026
Maintained: Hold
Price Target: $23.00 → $21.00
Current: $20.10
Upside: +4.48%
Integral Diagnostics Limited
Aug 11, 2026
Maintained: Buy
Price Target: $3.70 → $3.50
Current: $2.33
Upside: +50.21%
Neuren Pharmaceuticals Limited
Aug 5, 2026
Maintained: Buy
Price Target: $28.80 → $29.40
Current: $21.02
Upside: +39.87%
Clinuvel Pharmaceuticals Limited
Jul 28, 2026
Maintained: Buy
Price Target: $39.20 → $40.80
Current: $9.18
Upside: +344.44%
Mesoblast Limited
Jul 28, 2026
Maintained: Buy
Price Target: $2.80 → $3.00
Current: $2.41
Upside: +24.48%
Jul 28, 2026
Maintained: Hold
Price Target: $34.50 → $39.80
Current: $50.06
Upside: -20.50%
Jul 28, 2026
Maintained: Buy
Price Target: $5.00 → $5.60
Current: $2.34
Upside: +139.32%
Jul 28, 2026
Maintained: Buy
Price Target: $0.80 → $0.83
Current: $0.67
Upside: +23.88%
May 5, 2026
Maintained: Buy
Price Target: $3.05 → $3.30
Current: $2.62
Upside: +25.95%
Mar 13, 2026
Downgraded: Hold
Price Target: $2.10 → $0.04
Current: $0.05
Upside: -20.00%
Dec 6, 2022
Downgraded: Hold
Price Target: n/a
Current: $16.84
Upside: n/a
Apr 8, 2021
Downgraded: Hold
Price Target: n/a
Current: $14.35
Upside: n/a